DE69630798D1 - Aerosolzusammensetzungen - Google Patents

Aerosolzusammensetzungen

Info

Publication number
DE69630798D1
DE69630798D1 DE69630798T DE69630798T DE69630798D1 DE 69630798 D1 DE69630798 D1 DE 69630798D1 DE 69630798 T DE69630798 T DE 69630798T DE 69630798 T DE69630798 T DE 69630798T DE 69630798 D1 DE69630798 D1 DE 69630798D1
Authority
DE
Germany
Prior art keywords
liquefied hydrofluoroalkane
fatty acid
active ingredient
medium
chain fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69630798T
Other languages
English (en)
Other versions
DE69630798T2 (de
Inventor
Saburo Murata
Fumio Shimojo
Yuji Tokunaga
Takehisa Hata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of DE69630798D1 publication Critical patent/DE69630798D1/de
Application granted granted Critical
Publication of DE69630798T2 publication Critical patent/DE69630798T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69630798T 1995-09-19 1996-09-18 Aerosolzusammensetzungen Expired - Lifetime DE69630798T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23934295 1995-09-19
JP23934295 1995-09-19
PCT/JP1996/002670 WO1997010806A1 (en) 1995-09-19 1996-09-18 Aerosol compositions

Publications (2)

Publication Number Publication Date
DE69630798D1 true DE69630798D1 (de) 2003-12-24
DE69630798T2 DE69630798T2 (de) 2004-09-23

Family

ID=17043318

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630798T Expired - Lifetime DE69630798T2 (de) 1995-09-19 1996-09-18 Aerosolzusammensetzungen

Country Status (16)

Country Link
US (2) US6361760B1 (de)
EP (1) EP0851753B1 (de)
JP (2) JP3362394B2 (de)
KR (1) KR100523754B1 (de)
CN (1) CN1137680C (de)
AT (1) ATE254450T1 (de)
AU (1) AU719613B2 (de)
CA (1) CA2232378C (de)
DE (1) DE69630798T2 (de)
DK (1) DK0851753T3 (de)
ES (1) ES2206590T3 (de)
HK (1) HK1017845A1 (de)
PT (1) PT851753E (de)
TW (1) TW429153B (de)
WO (1) WO1997010806A1 (de)
ZA (1) ZA967887B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284226B1 (en) * 1997-03-14 2001-09-04 Fujisawa Pharmaceutical Co., Ltd. Aerosol composition containing middle-chain fatty acid triglyceride dispersant
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
CA2488013A1 (en) * 2002-05-30 2003-12-11 Celgene Corporation Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
AU2002952559A0 (en) * 2002-11-08 2002-11-21 Fujisawa Pharmaceutical Co., Ltd. New use
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US20040230272A1 (en) * 2003-04-11 2004-11-18 Cates Adam W. Subcutaneous lead with temporary pharmacological agents
MXPA05013324A (es) * 2003-06-10 2006-03-09 Astellas Pharma Inc Preparacion de aerosol comprendiendo un anexo que incluye una composicion de aerosol conteniendo compuesto macrolido.
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
CN1901903A (zh) * 2003-11-06 2007-01-24 细胞基因公司 用于治疗和控制石棉相关性疾病和病症的包含jnk抑制剂的组合物以及其使用方法
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005063242A1 (en) * 2003-12-30 2005-07-14 Astellas Pharma Inc. Use of macrolides for treating or preventing airflow obstruction
ZA200704889B (en) * 2004-11-23 2008-09-25 Celgene Corp JNK inhibitors for treatment of CNS injury
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8637070B2 (en) * 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
EP2001438A2 (de) 2006-02-09 2008-12-17 Macusight, Inc. Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
ES2435197T3 (es) 2007-01-10 2013-12-16 Board Of Regents, The University Of Texas System Administración mejorada de composiciones de fármacos inmunosupresores para la administración por vía pulmonar
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
KR20110096538A (ko) * 2008-11-04 2011-08-30 씨아이피엘에이 엘티디. 약제학적 에어로졸 조성물
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
EP2501716B1 (de) 2009-11-19 2015-01-21 Solis Biodyne Zusammensetzungen zur erhöhung der Polypeptidstabilität und -aktivität sowie zugehörige Verfahren
US20110318277A1 (en) * 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
EP4338797A3 (de) 2011-12-02 2024-06-12 Armagen, Inc. Verfahren und zusammensetzungen zur erhöhung der arylsulfatase-a-aktivität im zns
EP3730516A1 (de) 2013-07-22 2020-10-28 Armagen, Inc. Verfahren und zusammensetzungen zur erhöhung der enzymaktivität im zns
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
EP0406791B1 (de) 1989-07-05 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Wässriges flüssiges Mittel zur äusserlichen Anwendung
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
PH31204A (en) 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
AU8910891A (en) 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
JP3520517B2 (ja) 1992-11-18 2004-04-19 藤沢薬品工業株式会社 医薬用持続性製剤
JPH06345646A (ja) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US5681501A (en) * 1995-10-11 1997-10-28 E. I. Du Pont De Nemours And Company Compositions including a hydrofluoropropane
US6284226B1 (en) * 1997-03-14 2001-09-04 Fujisawa Pharmaceutical Co., Ltd. Aerosol composition containing middle-chain fatty acid triglyceride dispersant
CA2284988A1 (en) 1997-04-11 1998-10-22 Fujisawa Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
JP2000505050A (ja) 2000-04-25
PT851753E (pt) 2004-04-30
KR100523754B1 (ko) 2007-06-04
CA2232378C (en) 2009-04-14
KR19990044656A (ko) 1999-06-25
AU719613B2 (en) 2000-05-11
ATE254450T1 (de) 2003-12-15
ES2206590T3 (es) 2004-05-16
CN1201384A (zh) 1998-12-09
EP0851753A1 (de) 1998-07-08
US20020061906A1 (en) 2002-05-23
TW429153B (en) 2001-04-11
HK1017845A1 (en) 1999-12-03
ZA967887B (en) 1997-04-07
WO1997010806A1 (en) 1997-03-27
CN1137680C (zh) 2004-02-11
JPH09143054A (ja) 1997-06-03
CA2232378A1 (en) 1997-03-27
US6524556B2 (en) 2003-02-25
DK0851753T3 (da) 2004-03-15
JP3362394B2 (ja) 2003-01-07
AU6999896A (en) 1997-04-09
DE69630798T2 (de) 2004-09-23
EP0851753B1 (de) 2003-11-19
US6361760B1 (en) 2002-03-26
JP3266005B2 (ja) 2002-03-18

Similar Documents

Publication Publication Date Title
DE69630798D1 (de) Aerosolzusammensetzungen
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
GB2062465B (en) Topical preparation containing nitroglycerine and optionally other medicaments
AU662128B2 (en) New bi- and tricyclic aminoalcohol esters, their preparation and their use in medicaments
YU86001A (sh) Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
NZ330369A (en) aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester
MX9606501A (es) Composiciones antifungosas y curativas para heridas y metodos para preparar y utilizar las mismas.
BR9805993A (pt) Composição farmacêutica de aerosol.
KR930007444A (ko) 4-비페닐아세트 산(bpaa)를 함유하는 제약학적 조성물
CO5180575A1 (es) Composiciones antibacterianas orales de lupulona hidrogenda estable
MX9606502A (es) Composiciones antiqueratoliticas y curativas para heridas y metodos para preparar y utilizar las mismas.
JPS5659710A (en) Preventive and remedy for psoriasis
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
FI962056A0 (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
EP0968713A4 (de) Isosorbidnitrat enthaltentende pflaster
AU8740198A (en) Inhibitor and preservative formulation
EP0966958A4 (de) Aerosol-präparation
ES456094A1 (es) Un procedimiento para la preparacion de 2-acetoxi-benzoato de 2-(carbamoil) fenilo.
AU528211B2 (en) Synergistic analgesic compositions of suprofen
JPS5762220A (en) Embrocation for external use
KR910016314A (ko) 항생활성 성분의 치과용 국소지속성 투여조성물
IE811773L (en) Pharmaceutical comosition containing imidazolesalicylate
KR900009086A (ko) 정맥확장증 치료용 조서물 및 그의 제조방법
CA2066945A1 (en) Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP